Literature DB >> 22661309

High fat-induced obesity associated with insulin-resistance increases FGF-2 content and causes stromal hyperplasia in rat ventral prostate.

Daniele Lisboa Ribeiro1, Maria Etelvina Pinto, Samantha Yuri Maeda, Sebastião Roberto Taboga, Rejane Maira Góes.   

Abstract

Obesity affects sex hormone secretion, which can negatively influence prostatic structure, homeostasis, and disease. This investigation aimed to evaluate the repercussions of obesity induced by a high-fat diet on the rat prostate, with or without treatment with the aromatase inhibitor, Letrozole. Adult Wistar rats were fed a high-fat diet (20% saturated fat, O) for 15 weeks to induce obesity or received a balanced diet (4% fat, C). Then, a group of C and O rats were daily treated with Letrozole (1 mg/kg b.w. per day) for 2 weeks (CL and OL, respectively). Subsequently, ventral prostate was processed for analysis by transmission electron microscopy, immunohistochemistry, and Western blotting. Obesity decreased 70% of the testosterone plasma level. The prostate showed epithelial atrophy and dilated acini in the intermediate portion and epithelial wrinkling in the distal tips. The relative frequency of smooth muscle α-actin in the O group increased by 67%. Ultrastructurally, epithelial cells in obese animals presented altered secretory organelles, lipid droplets, and thicker subjacent fibromuscular layer. Letrozole treatment caused a partial restoration of the prostatic changes caused by obesity. Obesity increased the prostatic content of fibroblast growth factor-2 (FGF-2) by 150%, and Letrozole treatment increased this protein even more in the control and obese groups. This investigation shows that obesity provokes structural and ultrastructural changes in the epithelium of rat prostate; these changes might affect gland homeostasis and physiology. The epithelial and smooth muscle cell hyperplasia and increased FGF-2 expression observed in this experimental model of obesity/insulin-resistance might explain the high frequency of benign prostatic hyperplasia in insulin-resistant men.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22661309     DOI: 10.1007/s00441-012-1420-x

Source DB:  PubMed          Journal:  Cell Tissue Res        ISSN: 0302-766X            Impact factor:   5.249


  6 in total

1.  Prostate hyperplasia caused by long-term obesity is characterized by high deposition of extracellular matrix and increased content of MMP-9 and VEGF.

Authors:  Silas Amâncio Silva; Marina Guimarães Gobbo; Maria Etelvina Pinto-Fochi; Alex Rafacho; Sebastião Roberto Taboga; Eduardo Alves Almeida; Rejane Maira Góes; Daniele Lisboa Ribeiro
Journal:  Int J Exp Pathol       Date:  2014-12-21       Impact factor: 1.925

Review 2.  Testosterone deficiency, insulin-resistant obesity and cognitive function.

Authors:  Hiranya Pintana; Nipon Chattipakorn; Siriporn Chattipakorn
Journal:  Metab Brain Dis       Date:  2015-02-24       Impact factor: 3.584

3.  Obesity and metabolic dysfunction severely influence prostate cell function: role of insulin and IGF1.

Authors:  Fernando L-López; André Sarmento-Cabral; Vicente Herrero-Aguayo; Manuel D Gahete; Justo P Castaño; Raúl M Luque
Journal:  J Cell Mol Med       Date:  2017-02-28       Impact factor: 5.310

4.  Parental High-Fat Diet Promotes Inflammatory and Senescence-Related Changes in Prostate.

Authors:  Kulbhushan Tikoo; Ajit Vikram; Shweta Shrivastava; Gopabandhu Jena; Heta Shah; Richa Chhabra
Journal:  Oxid Med Cell Longev       Date:  2017-02-05       Impact factor: 6.543

5.  Renin-angiotensin system inhibitor attenuates oxidative stress induced human coronary artery endothelial cell dysfunction via the PI3K/AKT/mTOR pathway.

Authors:  Xuekun Shi; Yuhua Guan; Shaoyan Jiang; Tiandong Li; Bing Sun; Huan Cheng
Journal:  Arch Med Sci       Date:  2018-03-08       Impact factor: 3.318

6.  Effect of sildenafil citrate in testosterone induced benign prostate hyperplasia rat model.

Authors:  Selahattin Çalışkan; Muzaffer Oğuz Keleş; Metin İshak Öztürk; Musab Ali Kutluhan; Olgu Enis Tok; Feriha Ercan; Muhammet İhsan Karaman
Journal:  Turk J Urol       Date:  2017-12-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.